Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win

Sanofi, which is collaborating on the drug with Regeneron , said in a statement on Monday that a second Dupixent phase 3 trial for COPD, short for chronic obstructive pulmonary disease, showed the drug reduced exacerbations of the disease by 34 per cent.